Scribe Therapeutics, Inc.
SCTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001853921
No open-market purchases or sales by Scribe Therapeutics, Inc. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q3 2026, worth $297.1M in total; ARK Invest is the only superinvestor holding it.
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:22 AM ET
No financial statements
Scribe Therapeutics, Inc. has no annual statements on file yet. See the quarterly statements.